Introduction {#s02}
============

Regulated cell death has been understood as a concept for decades, with apoptosis being the first well-defined process in which cells dismantle themselves in a process that is generally immunologically quiet ([@bib72]; [@bib27]). Apoptosis is induced homeostatically and upon exposure to a wide variety of insults, leading to the activation of initiator caspases (caspase-8, -9, -10) and effector caspases (caspase-3, -6, -7), resulting in a nonlytic cell death characterized by membrane blebbing, cell shrinkage, and chromosomal condensation ([@bib27]). While apoptosis facilitates the controlled degradation of intracellular proteins and organelles, pyroptosis and necroptosis lead to cell lysis and the release of a wide range of intracellular components and inflammatory cytokines. We focus in this review on the lytic forms of cell death (pyroptosis and necroptosis) and the consequences of their cytokine release, with an eye toward new ways of treating inflammatory diseases.

Unlike apoptotic cell death, in which plasma membrane integrity is maintained and intracellular components are sequestered, pyroptosis is a lytic form of cell death that, through a tightly regulated pathway, activates and releases the potent cytokines IL-1β and IL-18 ([Fig. 1](#fig1){ref-type="fig"}; [@bib24]; [@bib22]; [@bib16]; [@bib94]). Pyroptosis plays a major role in the control of intracellular pathogens by destroying their replicative niche and driving immune responses through the release of matured cytokines ([@bib91]). Like apoptosis, pyroptosis is regulated by caspases, in particular caspase-1 and caspase-11 (in mice) or caspase-1/4/5 (in humans). Caspase-4/5/11 binds intracellular LPS directly, leading to cleavage of the substrate gasdermin D (GSDMD), the recently discovered executioner of pyroptosis ([@bib48]; [@bib71]; [@bib124]). Upon cleavage, the autoinhibitory C-terminal domain of GSDMD is released from the pore-forming N-terminal domain, leading to insertion of the GSDMD N-terminal domain into the plasma membrane and oligomerization with other GSDMD fragments, thereby generating a large pore 10--20 nm in diameter ([@bib26]). Similar to caspase-4/5/11, caspase-1 activation by upstream sensor proteins leads to caspase-1--mediated cleavage of GSDMD. The upstream regulators of caspase-1 activation differ in their specificity to different ligands and cellular states and include the proteins NLRP3, NLRC4, AIM2, NLRP1, and pyrin, with other related proteins being suggested as additional sensors ([@bib108]). A subset of these sensors (NLRP3, AIM2, and pyrin) require the adaptor protein ASC to activate caspase-1 after ligand sensing.

![**Overview of pyroptosis.** Pyroptosis is mediated by the inflammasome sensor proteins NLRC4, NLRP1, AIM2, Pyrin, and NLRP3, leading to activation of caspase-1. The NLRP1 and NLRC4 sensor proteins do not require the adaptor protein ASC, while the remaining sensors require ASC to oligomerize with caspase-1. Caspase-1 directly cleaves GSDMD to release the autoinhibitory C-terminal domain from its pore-forming N-terminal domain and also cleaves pro-IL-1β and pro-IL-18 into their active forms, which are released through the GSDMD pore. Caspase-11 binding to intracellular LPS activates caspase-11 to cleave GSDMD, which drives pore formation that leads to cell lysis and downstream NLRP3 inflammasome activation through the loss of ion homeostasis. dsDNA, double-stranded DNA.](JEM_20181892_Fig1){#fig1}

A single specific trigger for NLRP3 activation is not known, but many cellular insults induce NLRP3 inflammasome activation and cleavage of caspase-1, including loss of cellular ion homeostasis and plasma membrane disruption ([@bib65]; [@bib49]; [@bib58]). NLRC4 is activated by a set of sensor proteins including human NAIP/mouse NAIP1, NAIP2, and NAIP5/6, which recognize the bacterial type 3 secretion system (T3SS) needle, T3SS rod, or flagellin proteins, respectively ([@bib121]). The upstream NAIP proteins are also transcriptionally regulated by the transcription factor IRF8 ([@bib69]). The AIM2 inflammasome is activated by cytosolic double-stranded DNA binding with AIM2, which is detected upon viral entry into the cytosol or downstream of IRF1-mediated expression of IFN-stimulated genes that lyse intracellular bacteria ([@bib29]; [@bib54]; [@bib90]; [@bib96]). The mouse NLRP1b inflammasome is activated following proteolysis after exposure to *Bacillus anthracis* lethal toxin and DPP8/9 inhibitors ([@bib7]; [@bib103]). Newer studies have shown that endogenous human DPP9 binds and negatively regulates NLRP1, and a mutation in this binding domain is associated with NLRP1-associated autoinflammation with arthritis and dyskeratosis (NAIAD; [@bib151]). DPP8/9 inhibitors activate murine NLRP1b by inducing proteasomal degradation of the autoinhibitory N-terminal fragment, while anthrax lethal toxin functions by induction of N-end rule--mediated proteolysis of the N-terminal fragment of NLRP1 ([@bib104]; [@bib11]; [@bib21]; [@bib117]). Pyrin inflammasome activation is triggered by RhoA-GTPase--modifying toxins ([@bib142]). Concurrent with GSDMD cleavage, caspase-1 activation cleaves inactive pro-IL-1β and pro-IL-18 into their active forms. The formation of GSDMD pores in the plasma membrane facilitates the release of intracellular contents and mature IL-1β and IL-18, leading to inflammatory signaling in responding cells, which can have both beneficial and detrimental effects. Following pore formation by GSDMD, other inflammatory cytokines and alarmins that do not need processing by caspase-1, such as IL-1α, IL-33, HMGB1, ATP, and ASC complexes, are released, further contributing to the inflammatory response ([@bib130]; [@bib5]; [@bib30]). Together, the majority of these inflammasome complexes function to expel intracellular pathogens from the cell or halt viral replication in addition to releasing inflammatory cytokines, serving a critical role in host defense. Excessive or dysregulated activation of these complexes can also be detrimental to the host and is associated with inflammatory diseases, as discussed later in this review.

Similar to pyroptosis, necroptosis is a lytic form of cell death that is activated by a different pathway. In cells where caspase-8 is inhibited or missing, inflammatory signaling via TNF superfamily receptors, IFNs, TLR3, or TLR4 can lead to the phosphorylation of RIPK1, RIPK3, and ultimately mixed-lineage kinase domain-like pseudokinase (MLKL; [Fig. 2](#fig2){ref-type="fig"}; [@bib53]; [@bib10]; [@bib47]; [@bib82]; [@bib135]; [@bib97]). Following phosphorylation, MLKL assembles into oligomers that create a channel in the plasma membrane, disrupting the ion homeostasis of the cell, similar to GSDMD-mediated lysis ([@bib53]; [@bib127]; [@bib150]; [@bib82]; [@bib135]). The conditions for necroptosis are fairly strict in comparison to pyroptosis, but recent research has identified scenarios in which this pathway is engaged. Physiologically, it seems that necroptosis plays a backup role for cell death when the apoptotic pathway becomes inhibited by pathogens, mutations, changes in the regulators of apoptosis, or cancer ([@bib107]). Due to the complicated role of Fas-associated protein with death domain (FADD), caspase-8, RIPK1, RIPK3, and MLKL in regulating this form of cell death and also in regulating cytokine production, it is difficult to definitively attribute necroptosis to the progression of many diseases. New mouse models, chemical inhibitors, and assays that probe for phosphorylation of MLKL are helping to advance our understanding of the role of necroptosis in driving diseases ([@bib107]; [@bib138]).

![**Cell death crosstalk overview.** Activation of ZBP1 recruits RIPK3, FADD, and caspase-8 to drive parallel cell death pathways of apoptosis and pyroptosis. NLRP3 activation leads to ASC and caspase-1 inflammasome assembly and cleavage of the pyroptosis executioner GSDMD. TNF-mediated cell death induces apoptosis via TRADD, RIPK1, RIPK3, caspase-8, caspase-3, and caspase-7, but, upon inhibition of caspase-8 (by zVAD), TNF drives RIPK1, RIPK3, and MLKL phosphorylation to drive necroptotic cell death. The nucleic acid binding protein ZBP1 can also be directly activated by viral infection (influenza A virus \[IAV\], HSV, mouse cytomegalovirus \[MCMV\], and vaccinia virus \[VV\]) to induce cell death through parallel pathways of necroptosis, apoptosis, and pyroptosis.](JEM_20181892_Fig2){#fig2}

Crosstalk between apoptosis, necroptosis, and pyroptosis makes it difficult to determine how each pathway contributes to complex inflammatory diseases ([Fig. 2](#fig2){ref-type="fig"}). For example, apoptosis signaling through FADD and caspase-8 has been shown to link signaling between TLRs and priming of the NLRP3 inflammasome, and many of the proteins of the apoptosis pathway also regulate necroptosis ([@bib27]; [@bib42]). In addition to caspase-8--mediated priming of the inflammasome, others have observed that caspase-8 can localize to caspase-1-- and ASC-containing specks, facilitating inflammasome activation and downstream cytokine maturation ([@bib40]; [@bib89]; [@bib68]). Treatment of colorectal cancer cells with the platinum-based, DNA-damaging chemotherapy drug lobaplatin resulted in caspase-3--dependent cleavage of GSDME, a second gasdermin family pore-forming protein ([@bib147]). Infection with *Yersinia spp.* has also revealed a role for caspase-8--mediated cleavage of GSDMD, suggesting this plays a previously understudied role in regulating crosstalk between apoptosis and pyroptosis ([@bib105]; [@bib118]). While recent studies have shown that crosstalk between apoptotic signaling pathways with necroptosis and pyroptosis occurs, we focus here on the lytic forms of cell death as the final outcome that drives inflammatory pathology. In human cell lines, others have found that MLKL ion channel formation can lead to NLRP3 inflammasome activation in a cell-intrinsic manner, suggesting that this crosstalk between necroptosis and pyroptosis plays a larger role than previously appreciated ([@bib15]; [@bib45]). Other recent studies have described key new players that regulate crosstalk between cell death pathways. Inhibition or loss of TAK1 leads to autocrine TNF-mediated RIPK1-dependent cell death through combined apoptosis, pyroptosis, and necroptosis pathways ([@bib88]). In some viral infections, it also appears that the protein ZBP1 can act as a master regulator of all three cell death pathways, which requires further study in other contexts ([@bib77]). Importantly, these lytic forms of cell death also regulate the release of inflammatory cytokines that have been targeted successfully in many disease treatments. New studies examining the executioners of pyroptosis and necroptosis and their crosstalk in different contexts will shed more light on their physiological relevance.

Monogenic inflammatory diseases {#s03}
===============================

Due to the potent inflammatory signaling role of IL-1 and IL-18, the dysregulated activation and release of these cytokines contribute to many diseases ([Table 1](#tbl1){ref-type="table"}). Well-characterized gain-of-function mutations in inflammasome sensors lead to excessive production of these cytokines and cell death, underlying the pathogenesis of a number of monogenic diseases. Gain-of-function mutations in pyrin are associated with the autoinflammatory disease familial Mediterranean fever (FMF) and drive the excessive release of IL-1β via GSDMD-mediated pyroptosis in a mouse model of FMF ([@bib122]; [@bib64]). While commonly treated with colchicine, recent work has shown that inhibition of IL-1 with anakinra (recombinant IL-1R antagonist), canakinumab (anti--IL-1β monoclonal antibody), or rilonacept (decoy IL-1R/IL1-RA/IgG1 fusion protein) can improve outcomes in colchicine-resistant FMF and that GSDMD inhibitors may also play a future role ([@bib131]). In addition to the role of pyroptosis-mediated IL-1 release, a recent study showed that TNF signaling promoted the expression of pyrin in a positive feedback loop ([@bib123]). Patients with FMF also exhibit elevated serum IL-18, but whether this promotes disease and is a promising target for inhibition is unclear ([@bib134]).

###### Monogenic autoinflammatory diseases

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  **Disease**                        **Key regulator**   **Treatment target**                **Reference**
  ---------------------------------- ------------------- ----------------------------------- -------------------------------------------------------------
  CAPS                               NLRP3\              IL-1β (canakinumab)\                [@bib36]; [@bib31]; [@bib78]; [@bib73]; [@bib14]; [@bib140]
                                     IL-1β\              IL-1R (anakinra)\                   
                                     GSDMD\              IL-1 decoy receptor (rilonacept)\   
                                                         NLRP3 (MCC950)?\                    
                                                         GSDMD?                              

  FMF and PAAND                      Pyrin\              IL-1R (anakinra)\                   [@bib46]; [@bib122], [@bib123]; [@bib131]
                                     IL-1β\              IL-1β (canakinumab)\                
                                     TNF\                IL-1 decoy receptor (rilonacept)\   
                                     IL-18?\             IL-18?\                             
                                     GSDMD               GSDMD?                              

  DIRA                               IL-1RA              IL-1R (anakinra)                    [@bib57]

  Blau syndrome/PGA                  NOD2\               IL-1R (anakinra)\                   [@bib4]; [@bib125]
                                     IL-1β               IL-1β (canakinumab)\                
                                                         TNF                                 

  MKD/HIDS                           MVK\                IL-1R (anakinra)\                   [@bib93]
                                     Pyrin\              IL-1β (canakinumab)                 
                                     IL-1β                                                   

  TRAPS                              TNFR\               IL-1R (anakinra)\                   [@bib57]
                                     IL-1β\              IL-1β (canakinumab)                 
                                     GSDMD?\                                                 
                                     MLKL?                                                   

  Majeed syndrome                    LPIN2-NLRP3\        IL-1R (anakinra)\                   [@bib57]
                                     IL-1β               IL-1β (canakinumab)                 

  PAPA syndrome                      PSTPIP1-Pyrin\      IL-1R (anakinra)\                   [@bib62]; [@bib93]
                                     IL-1β\              IL-1β (canakinumab)\                
                                     IL-18?              TNF                                 

  PFIT                               WDR1-Pyrin\         IL-18?                              [@bib126]
                                     IL-18\                                                  
                                     GSDMD?                                                  

  AIFEC                              NLRC4\              IL-18?                              [@bib114]
                                     IL-18\                                                  
                                     IL-1?\                                                  
                                     IFNγ?                                                   

  NAIAD                              NLRP1\              IL-1?\                              [@bib39]; [@bib151]
                                     DPP9                IL-18?\                             
                                                         NLRP1?\                             
                                                         GSDMD?                              

  NLRP12AD                           NLRP12\             IL-1R (anakinra)?                   [@bib56]
                                     IL-1\                                                   
                                     GSDMD?\                                                 
                                     TNF?                                                    

  Chronic proliferative dermatitis   Sharpin\            TNF?\                               [@bib52]; [@bib34]; [@bib33]; [@bib76]; [@bib111]; [@bib44]
                                     TNF\                RIPK1 (Necrostatin-1)?\             
                                     RIPK1\              RIPK3 (GSK-872)?\                   
                                     RIPK3\              MLKL (necrosulfonamide)\            
                                     MLKL\               IL-1R (anakinra)?\                  
                                     NLRP3\              NLRP3 (MCC950)?\                    
                                     IL-1R\              GSDMD?                              
                                     IL-1β                                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------

AIFEC, autoinflammation with infantile enterocolitis; DIRA, deficiency of IL-1R antagonist; HIDS, hyper IgD syndrome; MKD, mevalonate kinase deficiency; NLRP12AD, NLRP12-associated autoinflammatory disease; PAAND, Pyrin-associated autoinflammation with neutrophilic dermatoses; PAPA, pyogenic arthritis, pyoderma gangrenosum, and acne; PFIT, periodic fever, immunodeficiency, and thrombocytopenia; PGA, pediatric granulomatous arthritis; TRAPS, TNF receptor--associated periodic fever.

Autoinflammatory diseases associated with NLRP3 mutations, collectively described as cryopyrin-associated periodic syndromes (CAPS), include familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disorder/chronic infantile neurological, cutaneous, and articular syndrome ([@bib93]). Together, these diseases are associated with systemic inflammation, neutrophilia, fever, rashes, and joint pain and are successfully treated with anakinra, rilonacept, and canakinumab and may be treated with NLRP3 or GSDMD inhibitors in the future ([@bib78]; [@bib35]; [@bib14]; [@bib140]). In addition to FMF and CAPS, other well-characterized diseases driven by IL-1, including deficiency of IL-1R antagonist; Blau syndrome; mevalonate kinase deficiency; Majeed syndrome; and PAPA (pyogenic arthritis, pyoderma gangrenosum, and acne) syndrome, are effectively treated with IL-1 blockade, but may eventually also be treated by inhibiting GSDMD or IL-18.

Understanding the mechanism behind other monogenic diseases associated with excessive IL-1 or TNF production has led to successful treatment with neutralizing antibodies against these cytokines, summarized in [Table 1](#tbl1){ref-type="table"}. In TNF receptor-associated periodic syndrome, which is mediated by a mutation that causes hyperactivation of TNFR1, IL-1 blockade but not TNF blockade was shown to be effective in treating patients, suggesting that treatments targeting the downstream TNF-mediated cell death, possibly via inhibition of MLKL and GSDMD, may be effective alternatives ([@bib57]; [@bib32]). In mice, a mutation in *Sharpin* (*Sharpin*^cpdm^) causes mice to develop chronic proliferative dermatitis, which is driven by excessive TNF production, which leads to excessive epithelial cell apoptosis and inflammation that is promoted by RIPK1, RIPK3, MLKL, caspase-1/11, NLRP3, and IL-1β, suggesting that inhibition of cell death in this model may protect from similar skin disorders in humans ([@bib34]; [@bib76]; [@bib111]; [@bib44]). In humans, the NLRP1 P1214R mutation, adjacent to the autocleavage site F1212-S1213, is associated with NAIAD, and molecular studies have found that DPP9 binding to the NLRP1 FIIND domain is disrupted by this mutation, suggesting that the binding of DPP9 and possibly DPP9-mediated degradation of the autoinhibitory C-terminal fragment of NLRP1 is lost in this disease ([@bib39]; [@bib151]). Loss of the executioner of pyroptotic cell death, GSDMD, in mouse models of FMF and CAPS protects mice from disease, suggesting that inhibitors against GSDMD or other steps of the pyroptosis signaling cascade may also show therapeutic potential in other inflammatory disorders.

IL-1--mediated diseases {#s04}
=======================

Mutations in key regulators of the pyroptosis pathway are known to drive autoinflammatory diseases. In addition to monogenic diseases, other complex inflammatory diseases can be successfully treated with IL-1 blockade. These inflammatory diseases include Behcet's disease, Sweet's syndrome, Schnitzler's syndrome, adult-onset Still's disease, and juvenile idiopathic disease, summarized in [Table 2](#tbl2){ref-type="table"}. Because IL-1 is elevated in multiple inflammatory diseases, it is suspected to contribute to the progression of gout, rheumatoid arthritis, kidney disease, lung disease, cancer, and many others reviewed elsewhere ([@bib57]; [@bib6]).

###### Cell death--mediated inflammatory cytokine-driven diseases

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Disease**                                            **Key regulator**   **Treatment target**               **Reference**
  ------------------------------------------------------ ------------------- ---------------------------------- ----------------------------------------------------
  Behcet's disease                                       IL-1\               IL-1R (anakinra)\                  [@bib95]; [@bib133]
                                                         IL-18?              IL-1β (canakinumab)                

  Sweet's syndrome (including neutrophilic dermatoses)   PTPN6?\             IL-1α?\                            [@bib100]; [@bib84]
                                                         RIPK1\              GSDMD?\                            
                                                         IL-1α\              MLKL?\                             
                                                         MLKL?                                                  

  Schnitzler syndrome                                    IL-1β               IL-1R (anakinra)\                  [@bib19]
                                                                             IL-1β (canakinumab)\               
                                                                             IL-1 decoy receptor (rilonacept)   

  AOSD                                                   IL-1β\              IL-1R (anakinra)\                  \
                                                         IL-18?\             IL-1β (canakinumab)\               [@bib79]; [@bib60]
                                                                             IL-1 decoy receptor (rilonacept)   

  JIA/soJIA                                              IL-1                IL-1R (anakinra)\                  [@bib106]; [@bib12]
                                                                             IL-1β (canakinumab)\               
                                                                             IL-1 decoy (rilonacept)            

  HLH                                                    IL-1?\              IL-1R (anakinra)?\                 [@bib120]
                                                         IL-18?              IL-18?                             

  Osteomyelitis                                          IL-1β\              IL-1R (anakinra)?\                 [@bib85]; [@bib43]
                                                         NLRP3\              MLKL?                              
                                                         Caspase-8\                                             
                                                         MLKL?                                                  

  Lung cancer                                            IL-1β               IL-1β (canakinumab)                [@bib113]

  Cardiovascular diseases                                IL-1α?, IL-1β       IL-1β (canakinumab)                [@bib112]

  Gout                                                   NLRP3\              IL-1R (anakinra)?\                 [@bib17]
                                                         MSU crystals\       IL-1β (canakinumab)?\              
                                                         IL-1\               IL-1 decoy (rilonacept)?           
                                                         GSDMD\                                                 
                                                         MLKL?                                                  

  Kidney diseases                                        IL-18\              IL-18?\                            [@bib139]; [@bib8]; [@bib119]
                                                         IL-1β\              MLKL (necrosulfonamide)?\          
                                                         RIPK3\              GSDMD?                             
                                                         MLKL?\                                                 
                                                         GSDMD?                                                 

  Alzheimer's disease                                    NLRP3\              NLRP3 (MCC950)?\                   [@bib132]
                                                         ASC                 ASC?\                              
                                                                             GSDMD?                             

  Ischemic brain injury                                  NLRP3\              RIPK1 (Necrostatin-1)\             [@bib18]; [@bib9]; [@bib143]; [@bib109]; [@bib149]
                                                         NLRC4?\             RIPK3 (GSK-872)                    
                                                         GSDMD\                                                 
                                                         RIPK1\                                                 
                                                         RIPK3?\                                                
                                                         MLKL?                                                  

  Rheumatoid arthritis                                   TNF\                TNF                                [@bib145]; [@bib17]
                                                         IL-1?\                                                 
                                                         GSDMD?\                                                
                                                         MLKL?                                                  

  Septic shock                                           Caspase-11\         GSDMD?                             [@bib71]; [@bib63]; [@bib92]
                                                         GSDMD\                                                 
                                                         Caspase-8                                              

  Inflammatory bowel diseases                            MLKL?\              NLRP3 (MCC950)?\                   [@bib87]; [@bib81]
                                                         NLRP3\              IL-1α (MABp1)?\                    
                                                         IL-1α               MLKL (necrosulfonamide)?           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

AOSD, adult-onset Still's disease; HLH, hemophagocytic lympho-histiocytosis; JIA, juvenile idiopathic arthritis; soJIA, systemic-onset juvenile idiopathic arthritis.

The recently completed Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS), in which a large cohort of 10,061 patients was treated with canakinumab following myocardial infarction, found that neutralizing IL-1β--mediated inflammation reduced recurrent cardiovascular events ([@bib112]). In atherosclerotic disease, it is thought that cell death, pyroptosis, and necroptosis lead to instability of plaques, which further suggests that blockade of these cell death pathways or their cytokine release may provide protection ([@bib80]; [@bib144]). Following the completion of the study, a second analysis of the CANTOS data found that canakinumab also had a significant effect on reducing lung cancer incidence and mortality, which was an unexpected finding from the trial ([@bib113]). In the tumor microenvironment, IL-1--driven inflammation is thought to increase tumor invasiveness, metastasis, and growth ([@bib3]; [@bib38]; [@bib67]). Together, these data provide compelling evidence that inhibiting IL-1β can have profound benefits in humans. While the protection from lung cancer was observed in patients with atherosclerosis, future studies in other patient populations will determine whether IL-1β inhibition can broadly protect from this devastating disease.

While IL-1β is often implicated in IL-1--driven diseases, the IL-1 family of proteins contains many other members including IL-1α, IL-18, IL-33, IL-36α/β/γ, IL-37, and IL-38 ([@bib23]). Importantly, IL-1α and IL-1β both bind the IL-1R, but the role for IL-1α is poorly understood in most disease conditions. Treatments targeting the IL-1R or both IL-1α and IL-1β (as with IL-1R--blocking anakinra or the decoy IL-1R drug rilonacept) have shown great success, but future trials will examine whether targeting either IL-1α or IL-1β alone may provide additional benefits in specific disease models or reduce side effects of dual inhibition. An IL-1α--specific neutralizing antibody (bermekimab, MABp1) is currently in clinical trials to determine its effectiveness in multiple inflammatory diseases ([@bib23]). Unlike IL-1β, IL-1α does not require caspase-1--mediated cleavage for its activation and can be released from pyroptotic or necroptotic cells. In a mouse model of neutrophilic dermatosis (via mutation in PTPN6), both RIPK1-driven up-regulation of inflammatory cytokines and IL-1α promote disease independently of inflammasome signaling and RIPK3, raising the question of whether MLKL or GSDMD may cooperate in some way to facilitate the release of IL-1α ([@bib84]). In patients with colorectal cancer, bermekimab-mediated neutralization of IL-1α appears to protect against chemotherapy-induced weight loss ([@bib51]; [@bib102]). In patients with TNF blockade--resistant severe hidradenitis suppurativa, bermekimab also seems to reduce symptoms ([@bib66]). Blockade of IL-1α may also protect patients from psoriasis and is being studied ([@bib13]). More studies will likely reveal an important role for IL-1α in driving many other diseases independent from inflammasome-driven production of IL-1β.

IL-18--driven diseases {#s05}
======================

The second key cytokine processed by caspase-1 and released by pyroptosis is IL-18, a key costimulatory cytokine of NK and T cell IFNγ responses ([@bib23]). Interestingly, a subset of autoinflammatory diseases associated with mutations in the pyroptosis machinery are poorly responsive to IL-1 blockade and better treated with IL-18 blockade. Excessive release of IL-18 in diseases, including Behcet's disease, hemophagocytic histiocytosis (HLH) with macrophage activation syndrome, and NLRC4-mediated autoinflammation with infantile enterocolitis is thought to contribute to their pathology, suggesting that IL-18 blockade may be beneficial in treating these diseases ([@bib95]; [@bib120]; [@bib133]; [@bib114]). Blockade of IL-18 may be beneficial in the context of colitis, inflammatory bowel disease, or cardiac disease, but conflicting findings on harmful and beneficial roles for IL-18 require more study ([@bib148]; [@bib25]; [@bib61]; [@bib129]). IL-18 is also thought to contribute to the pathogenesis of a number of skin diseases, including psoriasis, atopic dermatitis, and lupus, but more definitive studies are needed to determine whether inhibition with IL-18 binding protein (IL-18BP) will be beneficial ([@bib79]). Blockade strategies include recombinant IL-18BP or neutralizing antibodies targeting IL-18. To date, it is not clear where IL-18 blockade or supplementation will be useful clinically, but ongoing clinical trials and mouse studies should reveal important contributions for this caspase-1--regulated cytokine.

Pyroptosis-driven diseases {#s06}
==========================

While it has been understood for years that caspase-1 regulates pyroptosis and inflammasome-dependent cytokine release upon activation of specific inflammasome complexes, the recent discovery of GSDMD as the executioner of pyroptosis provides a new way of studying the relative contributions of both pyroptotic cell death and functional cytokine release. This is particularly important in light of many recent studies showing that the apoptotic, necroptotic, and pyroptotic pathways interact. Therapeutically, inhibition of GSDMD directly may prevent the release of cytokines as well as other alarmins released as a consequence of pyroptotic cell death that also contribute to disease progression, such as IL-1α, IL-33, HMGB1, or ATP. This is of particular interest in the treatment of sepsis, which in mouse models is critically dependent on caspase-11 and GSDMD, suggesting inhibitors may be able to effectively treat patients and block the release of many of the inflammatory mediators of septic shock ([@bib71]; [@bib124]; [@bib110]). Recent studies have identified two potential inhibitors of GSDMD that may hold therapeutic value. A GSDMD-derived peptide inhibitor, Ac-FLTD-CMK, inhibits pyroptosis by acting as an uncleavable substrate ([@bib146]). Necrosulfonamide, an inhibitor that disrupts disulfide bonds in both GSDMD (Cys^191^) and human (but not murine) MLKL (Cys^86^), inhibits both pyroptosis and necroptosis, suggesting it may be useful to inhibit both cell death modalities in patients ([@bib110]). In the brain, microglia are proposed to release ASC specks, which can seed amyloid-β plaques, suggesting that pyroptosis may promote Alzheimer's disease ([@bib132]). Downstream inflammatory consequences of this release are likely to promote an inflammatory positive feedback loop. In mouse models of CAPS, FMF, and septic shock, GSDMD deficiency alone protects from disease, suggesting that cytokine inhibition may not be necessary in some diseases ([@bib71]; [@bib64]; [@bib140]). Interestingly, in the absence of GSDMD, apoptotic pathways are sometimes activated, which likely has important implications for negative regulation of cytokine release ([@bib128]). Future research will likely reveal other diseases that are promoted specifically by GSDMD-mediated pyroptosis and may lead to better treatments than specific cytokine blockade.

Necroptosis-driven diseases {#s07}
===========================

Compared with pyroptosis, where upstream caspase-1--mediated cleavage of its substrates IL-1β and IL-18 is required for their activity, necroptosis is not known to be associated with any specific processing of inflammatory mediators before cell lysis. Necroptosis is also generally considered a backup form of cell death when parts of the apoptotic pathway are inhibited by pathogens or inhibitors ([@bib107]). Interestingly, recent studies have shown that necroptosis (often determined by phospho-MLKL) plays a role in the pathogenesis of a number of diseases. Recent studies have shown that necroptosis promotes ischemic tissue damage. In kidneys, ischemia-reperfusion injury is promoted by RIPK3 and MLKL, apparently by regulating the cell death of renal proximal tubular cells, with subsequent recruitment of macrophages and NLRP3 inflammasome activation. Inhibitors targeting RIPK1, RIPK3, and MLKL appear to reduce this kidney damage, but MLKL deficiency alone does not necessarily protect from kidney reperfusion injury, suggesting there may be other interacting forms of cell death that drive injury ([@bib83]; [@bib101]; [@bib2]; [@bib8]). In the liver, alcohol-induced damage was reduced in the absence of RIPK3 and MLKL, suggesting that necroptosis promotes disease ([@bib115]; [@bib136]). During spinal injury, it has also been proposed that microglia undergo necroptosis and that treatment with necrosulfonamide can reduce phospho-MLKL and pathology ([@bib28]; [@bib55]; [@bib137]). In the mouse *Sharpin*^cpdm^ model, skin inflammation is driven by necroptosis via TNF, RIPK1, RIPK3, MLKL, and downstream inflammasome-mediated IL-1β ([@bib76]; [@bib111]; [@bib44]). Together, these studies suggest that necroptosis can initiate and drive multiple inflammatory diseases and may be an effective target for future therapies.

Implications of cell death crosstalk {#s08}
====================================

Pyroptosis and necroptosis both lead to lytic cell death after stimulation with inflammatory mediators such as pathogens, alarmins, and cytokines such as TNF. Genetic studies have shown that necroptotic signaling via RIPK3, MLKL, NLRP3, and caspase-1 leads to release of mature IL-1β independent of GSDMD ([@bib99]; [@bib15]; [@bib45]). Mechanistically, this occurs through MLKL-mediated plasma membrane disruption, efflux of potassium ions, and subsequent NLRP3 inflammasome-mediated maturation of IL-1β that can be released by necroptosis. In inflamed tissues, this likely contributes significantly to the development of inflammatory diseases. Earlier studies also hinted at crosstalk between apoptotic and pyroptotic pathways, finding that caspase-8 can drive inflammasome activation ([@bib89]; [@bib42], [@bib43]). During infections or under the condition of TAK1 inactivation, multiple cell death pathways can be engaged to prevent pathogen-mediated inhibition of cell death and facilitate effective immune responses ([@bib77]; [@bib88]; [@bib105]; [@bib118]; [@bib141]). Similarly, loss of TBK1 results in spontaneous cell death that is driven by RIPK1 ([@bib141]).

During multiple viral infections, the sensor ZBP1 coordinates parallel cell death pathways of necroptosis, apoptosis, and pyroptosis with potential to regulate cell death during other currently unknown diseases ([@bib77]; [@bib75]; [@bib86]; [@bib41]). In physiological conditions, it is not surprising that RIPK1- and RIPK3-mediated expression of inflammatory cytokines or induction of necroptosis indirectly promote further downstream apoptosis, necroptosis, or pyroptosis in other nearby cells. In cancer, for example, changes in the apoptotic death pathways likely change the form of cell death that occurs downstream of TNF or other inflammatory signals. A recent study showed that in colorectal cancer cells, lobaplatin treatment induces a unique caspase-3--mediated cleavage of GSDME, a pore-forming protein related to GSDMD, inducing a pyroptosis-like cell death ([@bib147]). In endotoxic shock, recent work has shown that the combined action of caspase-11 and caspase-8, independent of RIPK1 kinase activity and RIPK3, drive endotoxin-mediated pathology in the small intestine and spleen. In addition to these key molecules, production of TNF and type I IFNs also promoted caspase-8--dependent apoptosis in the endotoxic shock model, highlighting an important role for both pyroptosis and apoptosis ([@bib92]). This highlights the importance of understanding which particular cell death pathways are involved in each unique disease scenario ([@bib147]).

A key problem in treating multifactorial diseases such as chronic inflammatory bowel disease, rheumatoid arthritis, psoriasis, and many others is identifying which steps of the inflammatory process initiate and promote disease. The relative success of TNF blockade in treating many of these diseases suggests that TNF-driven inflammation and likely TNF-mediated apoptosis help to drive the disease, but some patients eventually need to discontinue TNF blockade to avoid serious infectious complications ([@bib74]; [@bib1]; [@bib145]; [@bib70]). Understanding whether TNF promotes increased apoptosis, necroptosis, pyroptosis, and cytokine release to promote disease may suggest alternative treatments. In ischemic brain injury, NLRC4, NLRP3, GSDMD, RIPK1, RIPK3, and MLKL have all been proposed to promote pyroptosis and necroptosis in microglia or neuronal cells, and necrostatin-1 (an inhibitor of RIPK1) has been shown to ameliorate injury, but the role of each death pathway needs closer study ([@bib18]; [@bib143]; [@bib109]; [@bib149]). In a model of osteomyelitis, mutations in PSTPIP2 lead to excessive TNF, osteoclastogenesis, and neutrophil recruitment that destroys bone in a caspase-8--, NLRP3-, and IL-1β--dependent manner, suggesting that crosstalk between the apoptotic, necroptotic, and pyroptotic pathways is occurring ([@bib85]; [@bib43]). Whether the executioner molecules GSDMD or MLKL also play a role in promoting PSTPIP2-mediated bone disease remains to be seen. These cytokines and pathways also likely promote inflammation associated with rheumatoid arthritis of the joints ([@bib59]; [@bib145]). Cancers are often driven by proinflammatory cytokine production, so future work may reveal interesting roles for the executioners MLKL and GSDMD in promoting tumor growth, invasiveness, and metastasis ([@bib3]; [@bib113]). Identifying the most upstream pathway in each of these diseases will help determine which treatments may be best for preventing or treating them.

Future perspectives {#s09}
===================

Better understanding of the molecular mechanisms regulating apoptosis, pyroptosis, necroptosis, and the executioner molecules of each pathway may lead to better treatment of inflammatory diseases driven by the release of inflammatory cytokines and alarmins. The extensive crosstalk that researchers have observed between each of these pathways also suggests that it will be difficult to specifically target the appropriate cell death pathway without first understanding the critical regulators of individual diseases. Indeed, when cells receive a lethal trigger, they will often set off multiple overlapping signal cascades that lead to a switch in cell death when one key molecule is inhibited, as exemplified by necroptosis. In addition to understanding which forms of cell death promote a particular disease, it will be important to understand how the release of inflammatory cytokines and alarmins also contributes. A major concern with any immunosuppressive approach targeting necroptosis or pyroptosis is that patients may become susceptible to opportunistic infections, so carefully balancing the immunosuppression with this risk is critical.

Emerging work on sublethal pyroptosis and necroptosis, where membrane repair through ESCRT negatively regulates cell lysis and cytokine release, presents an interesting new mechanism by which inflammatory diseases may be treated, though whether this pathway plays a major role is unclear ([@bib37]; [@bib116]). Other recent studies have hinted at new mechanisms of inflammatory cytokine release that are GSDMD independent or GSDMD dependent but cell lysis independent, although other studies show that GSDMD-dependent rupture is required for cytokine release ([@bib50]; [@bib98]; [@bib20]). The physiological relevance of these alternative pathways is unclear and requires further study. Armed with our current understanding of these pathways, novel therapeutics specifically targeting pyroptosis- and necroptosis-mediated cell death, their upstream regulators, the apoptosis pathway, and the availability of cytokine-neutralizing antibodies hold great promise to treat a wide range of inflammatory diseases.
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